Recent news on Entecavir

BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load ...  -  May 21, 2007
PR Newswire (press release),Discovered at Bristol-Myers Squibb, BARACLUDE(R) (entecavir) is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in

DMCH doc attends international conference on liver diseases  -  May 1, 2007
Ludhiana Newsline,Newly introduced anti-viral drugs like adefovir, entecavir and teluvidine are available presently for management of Hepatitis B. According to specialists,

Bristol-Myers Squibb relieved to see Plavix back on track  -  Apr 27, 2007
Pharma Times (subscription),Revenues from Baraclude (entecavir) for hepatitis B reached $45 million, compared to $11 million in first-quarter 2006. The company also raised its outlook

Bristol-Myers Squibb announces new results of Baraclude (entecavir ...  -  Apr 17, 2007
News-Medical.net,Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of

BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels ...  -  Apr 16, 2007
Drug Newswire (press release),Discovered at Bristol-Myers Squibb, BARACLUDE(R) (entecavir) is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in

Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R ...  -  Apr 16, 2007
Drug Newswire (press release),More than 700 patients across six studies initiated therapy on BARACLUDE(R) (entecavir) and were monitored for treatment response and resistance.

BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels ...  -  Apr 13, 2007
PR Newswire (press release),People taking BARACLUDE(R) (entecavir) should tell their healthcare provider right away if they feel very weak or tired, have unusual muscle pain,

BARACLUDE® (entecavir) Resulted in Undetectable Levels of ...  -  Apr 13, 2007
EndoNurse,This analysis evaluated BARACLUDE® (entecavir) in nucleoside-naive chronic HBeAg-negative patients who discontinued study therapy in ETV-027,

ANA380 Exhibits Activity In Vitro Against Multiple Clinically ...  -  Apr 16, 2007
Drug Newswire (press release),The study found that the in vitro antiviral potency of ANA380 against seven of nine mutants that were resistant to lamivudine, adefovir, entecavir or

Fresh from the Pipeline: Telbivudine  -  Apr 5, 2007
Nature.com (subscription),It has since been joined on the market by the nucleotide analogue adefovir dipivoxil (Hepsera; Gilead) and the nucleoside analogues entecavir (Baraclude;

Clinical Trials Update: April 20, 2007  -  Apr 20, 2007
Atlanta Journal Constitution (subscription),This is a study to evaluate the drug entecavir in subjects receiving a liver transplant because of chronic hepatitis B virus infection.

ANA380 Exhibits Activity In Vitro Against Multiple Clinically ...  -  Apr 13, 2007
PR-Inside.com (Pressemitteilung),...of ANA380 against seven of nine mutants that were resistant to lamivudine, adefovir, entecavir or telbivudine was not significantly different from the

Anadys Pharmaceuticals (ANDS) Higher After Positive Study Results  -  Apr 13, 2007
StreetInsider.com (subscription),In addition, two HBV mutants that have been associated with clinical failure to entecavir or telbivudine, respectively, showed only small decreases (5 and 7

Anadys Pharma Reports ANA380 Exhibits Activity In Vitro Against ...  -  Apr 13, 2007
Trading Markets,In addition, two HBV mutants that have been associated with clinical failure to entecavir or telbivudine, respectively, showed only small decreases in

Bristol-Myers Squibb Says Four-Year Data Demonstrate Low Incidence ...  -  Apr 14, 2007
Trading Markets,Baraclude (entecavir) is a prescription medicine used for chronic infection with hepatitis B virus or HBV in adults where the virus is multiplying and

Update on Opt-Out Testing and Initial Antiretroviral Therapy ...  -  Apr 2, 2007
Medscape (subscription)Guidelines for managing HIV and chronic hepatitis B virus (HBV) coinfection include the recommendation for entecavir when treating HBV alone.

Bristol-Myers Squibb Reports Positive Results For Baraclude ...  -  Apr 13, 2007
Trading Markets,...levels of hepatitis B virus in the blood, when treated with Baraclude or entecavir achieved viral suppression and liver enzyme or ALT normalization.

StreetInsider.com Pre-Open Movers 04/13  -  Apr 13, 2007
StreetInsider.com (subscription),...retains potency against multiple mutant strains of hepatitis B virus (HBV) which are resistant to lamivudine, adefovir, entecavir or telbivudine

HIV and Hepatitis Co-Infections Challenging  -  Apr 6, 2007
MedPage Today,...(Researchers reported at this year's Conference on Retroviruses and Opportunistic Infections that entecavir (Baraclude) may cause HIV resistance when used

Anti-HBV drug entecavir also active against HIV and promotes ...  -  Mar 1, 2007
Aidsmap,The hepatitis B drug entecavir (Baraclude) demonstrates activity against HIV and selects for mutations that confer resistance to certain antiretroviral

Baraclude (entecavir) Occurrence of a resistant HIV variant in a ...  -  Mar 6, 2007
PharmaLive.com (press release),...(CHMP) reminds healthcare professionals that Baraclude (entecavir) has not been evaluated for the treatment of patients with chronic hepatitis B virus

Safety Alert - Baraclude, entecavir tablets and oral solution  -  Feb 25, 2007
SpiritIndia,AIDS (Acquired Immunodeficiency Syndrome or Acquired Immune Deficiency Syndrome, sometimes written Aids) is a human disease characterized by progressive

Widely used hepatitis B drug spurs HIV drug resistance  -  Mar 12, 2007
Johns Hopkins Gazette,Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus.

New risk with hepatitis B drug  -  Mar 15, 2007
Bay Area Reporter,The drug is entecavir (Baraclude), which was approved by the Food and Drug Administration in March 2005 and quickly became the drug of choice in treating

HIV/Hepatitis Coinfection  -  Mar 13, 2007
Medscape (subscription)The second presentation involved some unexpected data concerning the use of entecavir in HIV/HBV-coinfected patients. Chloe Thio at the John Hopkins

Hepatitis B drug spurs HIV drug resistance  -  Mar 1, 2007
Newindpress (subscription),..."Our results show that entecavir is no different from any other that has been shown to be active against HIV - it breeds resistance rapidly,

Studies Examine Effects of Circumcision, Hepatitis B Treatment on ...  -  Mar 2, 2007
Kaiser network.org,Hepatitis B Treatment and Resistance to Antiretrovirals: The hepatitis B drug entecavir might increase HIV-positive people's likelihood of developing

Hepatitis B drug triggers HIV resistance  -  Mar 1, 2007
Pharmaceutical Business ReviewA Johns Hopkins study has found that the hepatitis B drug entecavir, widely used in patients co-infected with HIV, leads to cross-resistance to other

Single Patient Shows Baraclude May Be Linked to Risk for Resistant HIV  -  Feb 26, 2007
Medscape (subscription)February 26, 2007 — Entecavir (Baraclude tablets and oral solution) may be linked to a risk for HIV resistance in patients coinfected with hepatitis B virus

CROI: HIV Resistance Linked to Hepatitis Drug  -  Mar 1, 2007
MedPage Today,Explain to interested patients that entecavir (Baraclude) is recommended to treat hepatitis B in patients co-infected with HIV who are not on HIV therapy.

Hepatitis B drug boosts HIV-drug resistance  -  Mar 1, 2007
New Scientist (subscription),Chloe Thio and colleagues at Johns Hopkins University in Baltimore, Maryland, US, investigated the drug entecavir, a leading treatment for hepatitis B. Thio

Hepatitis B Drug Triggers HIV Drug Resistance  -  Feb 28, 2007
Atlanta Journal Constitution (subscription),..."The guidelines recommend entecavir as first-line therapy in HIV-infected patients who need their hepatitis B treated but not their HIV.

Hepatitis B drug boosts resistance to AIDS treatment  -  Feb 28, 2007
Focus News,Entecavir, a widely used drug to treat hepatitis B liver infections, quickly increases resistance to AIDS treatments in HIV-infected patients,

Revised Baraclude Labeling Approved  -  Feb 28, 2007
Facts and Comparisons,...of revisions to the Microbiology (Antiviral Activity) and Indications and Usage sections of the prescribing information for Baraclude (entecavir).

Factor V; Hepatitis B  -  Mar 14, 2007
Sarasota Herald-Tribune,Medicines for hepatitis B are entecavir, adefovir, lamivudine and interferon alpha. The newest medicine is telbivudine.

Health Canada issues warning on use of Baraclude alone in HIV ...  -  Feb 22, 2007
Aidsmap,Health Canada has issued a warning that the use of the hepatitis B drug entecavir (Baraclude) has been associated with the development of a

Hepatitis drug may be linked with resistant strain of HIV: Health ...  -  Feb 22, 2007
CBC Saskatchewan,Baraclude, which is sold under the brand name Entecavir, was authorized for use in Canada in June 2006 to treat hepatitis B in adults.

Hepatitis Meds May Be Linked To Drug Resistant HIV Canadian Health ...  -  Feb 21, 2007
365Gay.comBaraclude, the brand name for the drug entecavir, has been authorized for use in Canada since June 2006 for the treatment of adults with active chronic

Information Update - Health Canada examining information linking ...  -  Feb 21, 2007
CNW Telbec (Communiqués de presse),Baraclude (the brand name for the drug entecavir) has been authorized in Canada since June 2006 for the treatment of active chronic infection with Hepatitis

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Entecavir was approved for the treatment of hepatitis B in 2005, and data continue to be reported on the long-term outcomes of patients.

Three-Year Data Showed Low Incidence Of BARACLUDE® (Entecavir) ...  Nov 2, 2006
Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE® (entecavir) resistance monitoring program, which found the ... -Medical News Today (press release), Study Shows Treatment With BARACLUDE(R) (Entecavir) Resulted In ...  Oct 31, 2006
...hepatitis B e-antigen (HBeAg) positive patients, showing that patients receiving the oral antiviral therapy BARACLUDE(R) (entecavir) demonstrated greater viral ... -Medical News Today (press release), BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression To ...  Oct 31, 2006
Myers Squibb Company (NYSE: BMY) today announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE(R) (entecavir) suppressed viral ... -Medical News Today (press release), Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) ...  Oct 30, 2006
FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY - News) today announced three-year results of the BARACLUDE® (entecavir) resistance monitoring program ... -Yahoo! News (press release) Baraclude (Entecavir) Demonstrated Viral Suppression to ...  Oct 31, 2006
Bristol-Myers Squibb Company today announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE(R) (entecavir) suppressed viral load to ... -PharmaLive.com (press release), Scottish Medicines Consortium (SMC) To Accept Baraclude® ...  Oct 14, 2006
Pharmaceuticals Limited (Bristol-Myers Squibb) has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Baraclude® (entecavir) for use ... -Medical News Today (press release), Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) ...  Oct 30, 2006
The year three analysis evaluated those patients who received treatment with BARACLUDE(R) (entecavir) during the third year (n=152 for patients in nucleoside ... -Earthtimes.org BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to ...  Oct 30, 2006
Two patients in this cohort died, but these deaths were not attributed to BARACLUDE(R) (entecavir). ... About BARACLUDE(R) (entecavir). ... -Earthtimes.org Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) ...  Oct 30, 2006
30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE(R) (entecavir) resistance monitoring ... -PR Newswire (press release), Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) ...  Oct 31, 2006
MA, USA | Oct 30, 2006 | Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE(R) (entecavir) resistance monitoring ... -PipelineReview.com (press release), (PRN) - Polypore Sets Third Quarter 2006 Earnings Release and ...  Oct 30, 2006
...(PRN) - Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients ... [+. ... -Bolsamania.com, Bristol-Myers Squibb: plan A for hepatitis B treatment  Nov 1, 2006
...two classes of drugs used to treat chronic infection of hepatitis B, immunomodulators and nucleoside analogues, such as Baraclude (entecavir), Hespera (adefovir ... -Pharmaceutical Business Review Gilead Q3 2006 Earnings Call Transcript  Oct 18, 2006
One and half years after the launch of a competitor, entecavir from Bristol-Myers, Hepsera prescription volume continue to increase with the growth of 3% from ... -Seeking Alpha, (PRN) - The Allied Defense Group Files Second Quarter 2006 Form 10 ...  Oct 30, 2006
...[+]. (PRN) - BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort ... [+. ... -Bolsamania.com, Pharma Sector: Few Newsmakers Of The Week - Novartis, Abbott ...  Oct 28, 2006
...for HBV are GlaxoSmithKline's Epivir-HB (lamivudine), Gilead Sciences' Hepsera (adefovir), Bristol-Myers Squibb's Baraclude (entecavir), Schering Corp.'s ... -Trading Markets, NEWS RELEASE  Oct 31, 2006
Bristol-Myers Squibb Company (NYSE: BMY) recently announced three-year results of the BARACLUDE® (entecavir) resistance monitoring program, which found the ... -Financial News USA (press release), Baraclude® (entecavir) Now Available In The UK For Treatment Of ...  Sep 21, 2006
Bristol-Myers Squibb announced today that Baraclude® (entecavir) is now available in the UK on prescription for the treatment of chronic hepatitis B virus ... -Medical News Today

Baraclude® (entecavir) Now Available In The UK For  Sep 21, 2006
Baraclude, developed by Bristol-Myers Squibb, is an oral antiviral therapy that inhibits the replication of the hepatitis B virus (HBV). ... -Haber Sağlık

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Entecavir was approved for the treatment of hepatitis B in 2005, and data continue to be reported on the long-term outcomes of patients.

Hepatitis B Virus (HBV) Resistance  Jul 26, 2006
...to almost all other anti-HBV agents (Figure 2), as a stepwise accumulation of resistance mutations is required for most agents, with entecavir and tenofovir ... -Medscape (subscription)

Bristol Obtains Japan Approval For Baraclude, Treatment For ...  Aug 5, 2006
Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry ... -Medical News Today

Bristol Obtains Japan Approval for Baraclude, Treatment for ...  Aug 3, 2006
Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health ... -Japan Corporate News

Bristol Obtains Japan Approval for Baraclude, Treatment for ...  Aug 4, 2006
4, 2006--(JCN Newswire via COMTEX) --Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by ... -Therapeutics Daily (subscription)

B-MS stumbles on Plavix probe, 2Q results  Jul 28, 2006
...the antiviral arena - Atripla (efavirenz, emticitabine, tenofovir disoproxil fumarate), the RA therapy Orencia (abatacept), Baraclude (entecavir) for hepatitis ... -Pharma Times (subscription)



COMUNICADO: 96-Week Data Show Entecavir Demonstrates More Viral ...  Apr 28, 2006
Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week clinical trial results demonstrating that entecavir maintains more viral load suppression ... - Europa Press

96-Week Data Show Entecavir Demonstrates More Viral Suppression ...  Apr 28, 2006
Austria (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week clinical trial results demonstrating that entecavir maintains more ... - news aktuell (Pressemitteilung)

New hepatitis B drug  Apr 29, 2006
The newest oral medication, entecavir, has just been approved in Malaysia. ... Prof Rosmawati assures that things are better with entecavir. ... - Malaysia Star

Increasing Drug Resistance to Widely Used Treatment for Hepatitis ...  May 8, 2006
The new Pharmacor report entitled Hepatitis B Virus finds that the uptake of Bristol-Myers Squibb's Baraclude (entecavir), Gilead's Hepsera (adefovir dipivoxil ... - PR Newswire

Committee for Medicinal Products for Human Use Summary of Opinion ...  Apr 28, 2006
The active substance of Baraclude is entecavir, an antiviral substance which belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors ... - PharmaLive.com

(PRN) - Reminder - Standard Pacific Corp. Schedules 2006 First ...  Apr 28, 2006
...[+]. (PRN) - 96-Week Data Show Entecavir Demonstrates More Viral Suppression Compared to Lamivudine in Hepatitis B Infected E-Antigen Negative Patients ... [+. ... - Bolsamania.com



Novartis/Idenix: entering hepatitis B market  Feb 7, 2006
...therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol-Myers Squibb's Baraclude (entecavir), are able ... - Pharmaceutical Business Review

Tenofovir works as well for HBV in coinfected with 3TC resistance ...  Jan 27, 2006
Currently, two other oral anti-HBV drugs are approved in the United States - adefovir (Hepsera) and entecavir (Baraclude) - although only adefovir currently ... - Aidsmap

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional